The current stock price of FTRE is 13.76 USD. In the past month the price decreased by -14.43%. In the past year, price decreased by -0.6%.
ChartMill assigns a technical rating of 6 / 10 to FTRE. When comparing the yearly performance of all stocks, FTRE is one of the better performing stocks in the market, outperforming 80.02% of all stocks.
ChartMill assigns a fundamental rating of 2 / 10 to FTRE. FTRE may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months FTRE reported a non-GAAP Earnings per Share(EPS) of 0.51. The EPS increased by 45.71% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -37.01% | ||
| ROE | -174.74% | ||
| Debt/Equity | 1.81 |
16 analysts have analysed FTRE and the average price target is 17.14 USD. This implies a price increase of 24.53% is expected in the next year compared to the current price of 13.76.
For the next year, analysts expect an EPS growth of 62.32% and a revenue growth 0.91% for FTRE
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 21.82 | 205.423B | ||
| DHR | DANAHER CORP | 25.89 | 153.038B | ||
| BRKRP | BRUKER CORP - BRKR 6 3/8 09/01/28 | 151.16 | 49.868B | ||
| A | AGILENT TECHNOLOGIES INC | 21.36 | 36.146B | ||
| IQV | IQVIA HOLDINGS INC | 14.06 | 32.812B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 30.34 | 28.211B | ||
| WAT | WATERS CORP | 22.71 | 19.534B | ||
| ILMN | ILLUMINA INC | 23 | 17.916B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 31.22 | 17.908B | ||
| MEDP | MEDPACE HOLDINGS INC | 27.13 | 14.94B |
View all stocks in the Life Sciences Tools & Services Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
Fortrea Holdings, Inc. engages in the provision of clinical development and commercialization services. The company is headquartered in Durham, North Carolina and currently employs 14,500 full-time employees. The company went IPO on 2023-06-16. The firm is engaged in providing biopharmaceutical product and medical device development services to pharmaceutical, biotechnology and medical device customers. The firm offers customers flexible delivery models that include full service, functional service provider, and hybrid service structures. The company provides phase I-IV clinical trial management, clinical pharmacology and consulting services. The firm manages its business through a single segment, Clinical Services, that provides services across the clinical pharmacology and clinical development spectrum. The firm has access to all key markets worldwide through a footprint of primary office locations in five countries (the United States, the United Kingdom, China, India and Singapore) with field operations in other jurisdictions worldwide.
FORTREA HOLDINGS INC
8 Moore Drive
Durham NORTH CAROLINA US
Employees: 14500
Phone: 13026365400
Fortrea Holdings, Inc. engages in the provision of clinical development and commercialization services. The company is headquartered in Durham, North Carolina and currently employs 14,500 full-time employees. The company went IPO on 2023-06-16. The firm is engaged in providing biopharmaceutical product and medical device development services to pharmaceutical, biotechnology and medical device customers. The firm offers customers flexible delivery models that include full service, functional service provider, and hybrid service structures. The company provides phase I-IV clinical trial management, clinical pharmacology and consulting services. The firm manages its business through a single segment, Clinical Services, that provides services across the clinical pharmacology and clinical development spectrum. The firm has access to all key markets worldwide through a footprint of primary office locations in five countries (the United States, the United Kingdom, China, India and Singapore) with field operations in other jurisdictions worldwide.
The current stock price of FTRE is 13.76 USD. The price decreased by -7.53% in the last trading session.
FTRE does not pay a dividend.
FTRE has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
The Revenue of FORTREA HOLDINGS INC (FTRE) is expected to grow by 0.91% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
FORTREA HOLDINGS INC (FTRE) has a market capitalization of 1.27B USD. This makes FTRE a Small Cap stock.
The outstanding short interest for FORTREA HOLDINGS INC (FTRE) is 9.61% of its float.